2.16
병태생리
제2형 당뇨병(T2DM)은 인슐린 저항성과 진행성 있는 췌장 β세포 기능 장애를 특징으로 하여 포도당 항상성 저하를 초래하는 만성 대사 질환입니다. 이는 유전적 소인, 환경 요인, 과도한 영양이나 좌식 생활 같은 대사 스트레스 요인 간의 상호작용에서 발생합니다.
…
제2형 당뇨병은 인슐린 저항성과 진행성 췌장 베타세포 기능 장애가 특징인 만성 진행성 대사 질환으로, 포도당 조절 장애를 초래합니다.
인슐린 저항성은 처음에 골격근, 간, 지방 조직에서 발생합니다.
식후 포도당 흡수의 주요 부위인 골격근은 인슐린에 덜 반응하여 포도당 제거율이 감소합니다.
한편, 간 인슐린 저항성은 식사 후에도 포도당 생성이 계속되는 결과를 낳습니다.
인슐린 신호 저하와 알파 세포 조절 장애는 글루카곤 수치를 높여 간 포도당 생산량을 더욱 증가시킵니다.
이에 대응하여 베타 세포는 처음에 인슐린 분비를 증가시켜 보상합니다; 그러나 장기간 고혈당과 대사 스트레스에 노출되면 베타세포 기능이 점차 저하됩니다.
지방 조직에서 인슐린 저항성은 지방분해를 증가시켜 순환하는 자유 지방산을 증가시키고, 이는 지독성 작용을 통해 인슐린 저항성을 악화시킵니다.
이러한 상호 연결된 대사 장애들이 만성 고혈당을 지속시킵니다.
View the full transcript and gain access to JoVE Core videos
Q1: What causes insulin resistance in type 2 diabetes?
Insulin resistance develops initially in skeletal muscle, liver, and adipose tissue. Skeletal muscle becomes less responsive to insulin, reducing glucose clearance despite normal or high insulin levels. The liver fails to suppress gluconeogenesis, causing excess glucose production. In adipose tissue, insulin resistance increases lipolysis, elevating free fatty acids that worsen insulin resistance through lipotoxic effects.
Q2: How does hepatic glucose output increase in type 2 diabetes?
Hepatic insulin resistance prevents the liver from suppressing glucose production after meals. Additionally, impaired insulin signaling and dysregulated alpha cells elevate glucagon levels, further increasing hepatic glucose output. This dual mechanism sustains chronic hyperglycemia by maintaining elevated fasting and postprandial glucose levels despite the body's attempt to regulate blood sugar.
Q3: What happens to pancreatic beta cells over time in type 2 diabetes?
Beta cells initially compensate for insulin resistance by increasing insulin secretion. However, prolonged exposure to hyperglycemia and metabolic stress progressively impairs beta-cell function. Glucotoxicity, lipotoxicity, oxidative stress, and inflammation reduce beta-cell mass through apoptosis, leading to inadequate insulin secretion and worsening glucose control.
Q4: How do free fatty acids contribute to type 2 diabetes progression?
Elevated free fatty acids from increased adipose tissue lipolysis worsen hepatic insulin resistance and directly damage beta cells through lipotoxic effects. Reduced lipoprotein lipase activity contributes to diabetic dyslipidemia, characterized by high triglycerides, low HDL, and small dense LDL particles, further perpetuating metabolic dysfunction.
Q5: What role does skeletal muscle play in glucose regulation in type 2 diabetes?
Skeletal muscle is the primary site of postprandial glucose uptake. In type 2 diabetes, muscle insulin resistance reduces glucose clearance despite normal or elevated insulin levels. Additionally, muscle insulin resistance alters protein metabolism, increasing amino acid release that fuels gluconeogenesis, further elevating blood glucose.
Q6: How can type 2 diabetes lead to serious acute complications?
Stress hormones including cortisol and catecholamines worsen hyperglycemia and may trigger hyperosmolar hyperglycemic state or, rarely, diabetic ketoacidosis. Chronic hyperglycemia causes protein glycation, oxidative stress, and inflammation, leading to macrovascular complications such as coronary artery disease and stroke, as well as microvascular complications.
Q7: What are the long-term microvascular complications of type 2 diabetes?
Chronic hyperglycemia causes microvascular complications including diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy. These result from protein glycation, oxidative stress, and inflammation affecting small blood vessels and nerves. Understanding these complications is essential for recognizing clinical manifestations and diagnosis in affected patients.